Literature DB >> 6607792

Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.

M Shiraki, M Fujiwara, S Tomura.   

Abstract

Weekly injection of cyclophosphamide (Cy) into MRL/Mp-lpr/lpr (MRL/l) mice, at a dose of 10-20 mg/kg, from 1 month of age prevented the development of generalized lymph node enlargement, decreased serum levels of anti-DNA antibodies and immune complexes, and markedly prolonged their life span. Cy effectively suppressed enhanced differentiation of B cells, as evidenced by decreased number of immunoglobulin secreting cells in the spleen. Cy was also shown to suppress abnormal expansion of Thy-1 positive cells in lymphoid organs of MRL/1 mice. These results suggested that Cy prevented the development of murine lupus like syndrome in MRL/1 mice through suppression of spontaneous polyclonal B cell activation and also by reducing the number of T cells to exert excessive helper activity on B cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607792      PMCID: PMC1535818     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol.

Authors:  M Digeon; M Laver; J Riza; J F Bach
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

3.  The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice.

Authors:  E R Hurd; M Ziff
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 4.  A comparative immunologic analysis of several murine strains with autoimmune manifestations.

Authors:  A N Theofilopoulos; P J McConahey; S Izui; R A Eisenberg; A B Pereira; W D Creighton
Journal:  Clin Immunol Immunopathol       Date:  1980-03

5.  The in vitro and in vivo induction of anti-double-stranded DNA antibodies in normal and autoimmune mice.

Authors:  F Fish; M Ziff
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

6.  Anti-double strand (ds) DNA antibody formation by NZB/W (F1) spleen cells in a microculture system detected by solid phase radioimmunoassay.

Authors:  H Okudaira; E Terada; T Ogita; S Aotsuka; R Yokohari
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

7.  Immunological properties of athymic nude mice born from homozygous (nu/nu) parents.

Authors:  T Kuhara; M Fujiwara; K Sudo; K Suzuki; A Kawamura
Journal:  Lab Anim       Date:  1980-04       Impact factor: 2.471

8.  Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice.

Authors:  A D Steinberg; J B Roths; E D Murphy; R T Steinberg; E S Raveche
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

9.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Distribution of lymphocytes identified by surface markers in murine strains with systemic lupus erythematosus-like syndromes.

Authors:  A N Theofilopoulos; R A Eisenberg; M Bourdon; J S Crowell; F J Dixon
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

View more
  16 in total

1.  Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue.

Authors:  T Naito; T Kawamura; M Bannai; T Kosaka; H Kameyama; K Shimamura; O Hoshi; T Ushiki; K Hatakeyama; T Abo
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

2.  Sustained Immunosuppression Alters Olfactory Function in the MRL Model of CNS Lupus.

Authors:  Minesh Kapadia; Hui Zhao; Donglai Ma; Boris Sakic
Journal:  J Neuroimmune Pharmacol       Date:  2017-04-11       Impact factor: 4.147

3.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

4.  Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.

Authors:  Jeremy S Tilstra; Lyndsay Avery; Ashley V Menk; Rachael A Gordon; Shuchi Smita; Lawrence P Kane; Maria Chikina; Greg M Delgoffe; Mark J Shlomchik
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

5.  Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses.

Authors:  S Ito; M Ueno; M Arakawa; T Saito; T Aoyagi; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

6.  Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice.

Authors:  H Kamada; Y Takaoka; K Kitagaki; H Nagai
Journal:  Inflamm Res       Date:  1995-11       Impact factor: 4.575

7.  Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.

Authors:  S Ikehara; K Shimamura; T Aoyama; S Fujii; Y Hamashima
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

8.  Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen.

Authors:  M Shiraki; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

9.  Suppression of spontaneous murine lupus by inducing graft-versus-host reaction with CD8+ cells.

Authors:  S Ito; M Ueno; S Nishi; M Arakawa; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  Hippocampal damage in mouse and human forms of systemic autoimmune disease.

Authors:  David A Ballok; John Woulfe; Monalisa Sur; Michael Cyr; Boris Sakic
Journal:  Hippocampus       Date:  2004       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.